To address this barrier, we utilized pexidartinib, a small molecule inhibitor of CSF1R tyrosine kinase, in combination with viroimmunotherapy in the 67C-4 murine MPNST model, given the model’s immunogenic nature and previous sensitivity to our immune-modulating combination therapies (43). This evidence concerns the gene CSF1R and malignant peripheral nerve sheath tumor.